↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Träfflista för sökning "WFRF:(Macdonell A) "

Search: WFRF:(Macdonell A)

Result 1-10 of 21

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Jukema, JW, et al. (author) Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 74:9, s. 1167-1176 Journal article (peer-reviewed)
2.	Ray, KK, et al. (author) Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial 2019 In: The lancet. Diabetes & endocrinology. - 2213-8595 .- 2213-8587. ; 7:8, s. 618-628 Journal article (peer-reviewed)
3.	Roe, MT, et al. (author) Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes 2019 In: Circulation. - : Ovid Technologies (Wolters Kluwer Health). - 1524-4539 .- 0009-7322. ; 140:19, s. 1578-1589 Journal article (peer-reviewed)
4.	Szarek, M, et al. (author) Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial 2019 In: Circulation. Cardiovascular quality and outcomes. - : Ovid Technologies (Wolters Kluwer Health). - 1941-7705 .- 1941-7713. ; 12:11, s. e005858- Journal article (peer-reviewed)
5.	Szarek, M, et al. (author) Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 73:4, s. 387-396 Journal article (peer-reviewed)
6.	Goodman, SG, et al. (author) Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 74:9, s. 1177-1186 Journal article (peer-reviewed)
7.	Bittner, VA, et al. (author) Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome 2020 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 75:2, s. 133-144 Journal article (peer-reviewed)
8.	Schwartz, GG, et al. (author) Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome 2018 In: The New England journal of medicine. - : MASSACHUSETTS MEDICAL SOC. - 1533-4406 .- 0028-4793. ; 379:22, s. 2097-2107 Journal article (peer-reviewed)
9.	Calabresi, PA, et al. (author) The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL 2007 In: Neurology. - : Ovid Technologies (Wolters Kluwer Health). - 1526-632X .- 0028-3878. ; 69:14, s. 1391-1403 Journal article (peer-reviewed)
10.	Comi, G., et al. (author) Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies 2020 In: Multiple Sclerosis Journal. - : SAGE Publications. - 1352-4585 .- 1477-0970. ; 26:14, s. 1866-1876 Journal article (peer-reviewed)abstract Background: Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. Objective: To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alemtuzumab and Rebif (R) Efficacy in Multiple Sclerosis) studies and their extensions. Methods: Subgroups were based on the number of additional alemtuzumab courses received. Exclusion criteria: other disease-modifying therapy (DMT); Results: In the additional-courses groups, Courses 3 and 4 reduced annualized relapse rate (12 months before: 0.73 and 0.74, respectively; 12 months after: 0.07 and 0.08). For 36 months after Courses 3 and 4, 89% and 92% of patients were free of 6-month confirmed disability worsening, respectively, with 20% and 26% achieving 6-month confirmed disability improvement. Freedom from magnetic resonance imaging (MRI) disease activity increased after Courses 3 and 4 (12 months before: 43% and 53%, respectively; 12 months after: 73% and 74%). Safety was similar across groups; serious events occurred irrespective of the number of courses. Conclusion: Additional alemtuzumab courses significantly improved outcomes, without increased safety risks, in CARE-MS patients with continued disease activity after Course 2. How this compares to outcomes if treatment is switched to another DMT instead remains unknown.

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-10 of 21

Refine your search

Type of publication: journal article (14); conference paper (7)

Type of content: peer-reviewed (16); other academic/artistic (5)

Author/Editor: King, M. (8); Li, Y. (8); Schmidt, E. (8); Zaman, A. (8); Zhang, Z. (8); Zhu, H. (8); show more...; Guo, Y (8); Ahmed, H. (8); Kaiser, S. (8); Nikolaev, K. (8); Schwartz, M. (8); Kumar, A. (8); Robinson, S. (8); Zheng, Y. (8); Costa, F. (8); Das, S. (8); Diaz, R. (8); Mahajan, A. (8); Davies, R (8); Aggarwal, R. (8); Andersen, K (8); Diaz, A. (8); Cohen, S. (8); Rosenberg, M. (8); Gullestad, L (8); Hong, T. (8); Kumar, P. (8); Khan, A. (8); Davis, W. (8); Aboyans, V (8); Khan, M (8); Liu, SW (8); Pandey, A (8); Sarkar, D. (8); Hoffman, D (8); Takahashi, T. (8); Marx, R. (8); Bottcher, M. (8); White, M. (8); Seferovic, P (8); Wells, T (8); Katz, A. (8); Ito, K. (8); Kobayashi-, J (8); Harding, S (8); Huang, L. (8); Anderson, J (8); Vulic, D (8); Pearce, S (8); Gerber, J. (8); show less...

University: Karolinska Institutet (15); Uppsala University (9); University of Gothenburg (4); Chalmers University of Technology (2)

Language: English (21)

Research subject (UKÄ/SCB): Medical and Health Sciences (11); Natural sciences (3); Engineering and Technology (1); Social Sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view